OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients.
Zach
Otto
O
Krieger
Otto
O
Foedermayr
Mathilde
M
Zellhofer
Barbara
B
Lutz
Dieter
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense / Q000187:drug effects; D050811:Octamer Transcription Factor-1 / Q000235:genetics*; D010879:Piperazines / Q000009:adverse effects*; D020641:Polymorphism, Single Nucleotide / Q000187:drug effects; D011743:Pyrimidines / Q000009:adverse effects*; D055815:Young Adult
D001549:Benzamides; D050811:Octamer Transcription Factor-1; C494165:POU2F1 protein, human; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate